Hemab Therapeutics Holdings, Inc. Share Price
NASDAQ: COAGHemab Therapeutics Holdings, Inc. Stock Performance
Hemab Therapeutics Holdings, Inc. Share Price Today
As of 1 November 2026, Hemab Therapeutics Holdings, Inc.'s share price is $41.44. The stock opened at $41.16, compared to its previous close of $40.47. During today's trading session, Hemab Therapeutics Holdings, Inc.'s share price traded between $39.53 and $42.84, with an average price of $41.19. Over the past 52 weeks, the stock has recorded a high of $54.94 and a low of $23.50. In terms of performance, Hemab Therapeutics Holdings, Inc.'s share price has risen by 45.95% over the last six months and is up 45.95% on a year-on-year basis.
Hemab Therapeutics Holdings, Inc. Share Price Chart
Hemab Therapeutics Holdings, Inc. Quarterly Profit & Loss
All figures in USD
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Hemab Therapeutics Holdings, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Oct 2026 | $30.64 | $41.46 | +33.79% |
Sep 2026 | $44.85 | $30.99 | -37.34% |
Aug 2026 | $46.71 | $49.46 | +4.61% |
Jul 2026 | $34.86 | $47.28 | +29.11% |
Jun 2026 | $27.53 | $36.62 | +28.99% |
May 2026 | $27.04 | $28.39 | N/A |